Lupisulin M 50 Injection 100IU/ml is a biphasic insulin formulation comprising 50% Insulin Isophane and 50% Human Insulin, designed for the management of diabetes mellitus requiring insulin therapy. This combination provides both intermediate-acting and short-acting insulin components, facilitating effective glycemic control by addressing both basal and prandial insulin requirements. Insulin Isophane, the intermediate-acting component, ensures prolonged insulin activity, reducing the frequency of injections, while the human insulin component offers rapid onset to manage postprandial glucose excursions. Lupisulin M 50 is indicated for patients with type 1 and type 2 diabetes mellitus when diet, exercise, and oral hypoglycemic agents alone are insufficient to achieve adequate glycemic control. The injection should be administered subcutaneously, with dosage individualized based on the patient’s metabolic needs, blood glucose monitoring results, and glycemic control goals. Proper injection technique and rotation of injection sites are essential to minimize local adverse effects such as lipodystrophy. Hypoglycemia is the most common adverse effect and requires prompt recognition and management. Lupisulin M 50 should be used under medical supervision with regular monitoring of blood glucose levels to optimize therapy and minimize complications.